Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Robinson Cabello et al.|New England Journal of Medicine|2021Cited by 847
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A. Marzinke, Susan H. Eshleman, Beatriz Grinsztejn et al.|The Journal of Infectious Diseases|2021Cited by 129
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipelineLara E. Coelho, Beatriz Grinsztejn, Valdiléa G. Veloso et al.|The Lancet HIV|2019Cited by 106